Isarna Therapeutics' Series E - II Round

Isarna Therapeutics raised a round of funding on April 24, 2014.

Isarna Therapeutics has a commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. The company is advancing a unique pipeline of novel oligonucleo…

Articles about Isarna Therapeutics' Series E - II Round: